Merck’s KEYTRUDA approved as monotherapy in China for first-line treatment of certain patients with advanced NSCLC

This article was originally published here

This new indication was granted full approval based on the overall survival (OS) findings from the Phase 3 KEYNOTE-042 trial, including data from an extension of the global

The post Merck’s KEYTRUDA approved as monotherapy in China for first-line treatment of certain patients with advanced NSCLC appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply